Alumis
Update in progressALMS (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Alumis Inc. is a clinical‑stage biopharmaceutical company focused on medicines for autoimmune and immune-related disorders. It develops envudeucitinib, a TYK2 inhibitor for plaque psoriasis and systemic lupus erythematosus; A-005, a CNS-penetrant allosteric TYK2 inhibitor in Phase 1 for neuroinflammatory and neurodegenerative diseases; lonigutamab, an anti‑IGF‑1R antibody for thyroid eye disease; and IRF5 targeting approaches. Formerly Esker Therapeutics, renamed in 2022. Founded 2021, based in South San Francisco.
Company score
- Sentiment
- 0.21
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.09
- Governance
- -0.01
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.03
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.12
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEOMr. Martin Babler Ph.D.
- Founded2021
- Employees237
- Websitewww.alumis.com
Identifiers
- ISINUS0223071020
- FIGIBBG01J7X4PN2